Merus N.V. is a clinical-stage immuno-oncology company focused on developing innovative bispecific antibody therapeutics. With its proprietary technology platform, Merus aims to leverage the power of the immune system to fight cancer and other serious diseases. The company’s pipeline includes several promising candidates for the treatment of various cancers, offering hope for improved patient outcomes.
